Discounted Cash Flow (DCF) Analysis Levered
Health Catalyst, Inc. (HCAT)
$9.84
+0.07 (+0.72%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 112.57 | 154.94 | 188.85 | 241.93 | 276.24 | 346.54 | 434.74 | 545.39 | 684.21 | 858.35 |
---|---|---|---|---|---|---|---|---|---|---|
Revenue (%) | ||||||||||
Operating Cash Flow | -40.30 | -32.18 | -26.15 | -23.12 | -35.27 | -64.28 | -80.64 | -101.16 | -126.91 | -159.20 |
Operating Cash Flow (%) | ||||||||||
Capital Expenditure | -2.50 | -4.33 | -10.47 | -18.47 | -17.41 | -16.98 | -21.30 | -26.72 | -33.53 | -42.06 |
Capital Expenditure (%) | ||||||||||
Free Cash Flow | -42.80 | -36.52 | -36.61 | -41.59 | -52.68 | -81.26 | -101.94 | -127.88 | -160.43 | -201.26 |
Weighted Average Cost Of Capital
Share price | $ 9.84 |
---|---|
Beta | 1.300 |
Diluted Shares Outstanding | 54.08 |
Cost of Debt | |
Tax Rate | 3.02 |
After-tax Cost of Debt | 0.66% |
Risk-Free Rate | |
Market Risk Premium | |
Cost of Equity | 10.676 |
Total Debt | 247.97 |
Total Equity | 532.15 |
Total Capital | 780.12 |
Debt Weighting | 31.79 |
Equity Weighting | 68.21 |
Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
Revenue | 112.57 | 154.94 | 188.85 | 241.93 | 276.24 | 346.54 | 434.74 | 545.39 | 684.21 | 858.35 |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow | -40.30 | -32.18 | -26.15 | -23.12 | -35.27 | -64.28 | -80.64 | -101.16 | -126.91 | -159.20 |
Capital Expenditure | -2.50 | -4.33 | -10.47 | -18.47 | -17.41 | -16.98 | -21.30 | -26.72 | -33.53 | -42.06 |
Free Cash Flow | -42.80 | -36.52 | -36.61 | -41.59 | -52.68 | -81.26 | -101.94 | -127.88 | -160.43 | -201.26 |
WACC | ||||||||||
PV LFCF | -75.59 | -88.23 | -102.97 | -120.18 | -140.26 | |||||
SUM PV LFCF | -527.22 |
Terminal Value
Growth in perpetuity method: | |
---|---|
Long-term growth rate | |
WACC (%) | 7.49 |
Free cash flow (t + 1) | -205.29 |
Terminal Value | -3,739.32 |
Present Value of Terminal Value | -2,605.87 |
Intrinsic Value
Enterprise Value | -3,133.09 |
---|---|
Net Debt | 131.66 |
Equity Value | -3,264.75 |
Shares Outstanding | 54.08 |
Equity Value Per Share | -60.37 |